TG Therapeutics Inc (TGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
TG Therapeutics Inc (TGTX) Earnings: Report Dates and Results
TG Therapeutics (TGTX) is expected to report earnings on Jan 11, 2027. In the quarter ended Sep 30, 2026, TG Therapeutics reported EPS of $0.35, above the $0.28 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TGTX has an expected report date of Jan 11, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 300.0% above the $0.14 reported for the quarter ended Dec 31, 2025.
TGTX Earnings Call
The latest TGTX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, TGTX beat 11, missed 27 and matched 2. The widest gap in the table came in the quarter ended Sep 30, 2023, when EPS landed 630.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.35 | $0.28 | $0.19 - $0.35 | +25.00% | Beat | +118.7% | 4 | 0 up, 2 down | Nov 9, 2026 | N/A |
| Jun 30, 2026 | $0.05 | $0.41 | $0.31 - $0.61 | -87.80% | Miss | -70.6% | 5 | 5 up, 0 down | Aug 3, 2026 | $240.34M |
| Mar 31, 2026 | $0.18 | $0.28 | $0.12 - $0.46 | -35.71% | Miss | +500.0% | 4 | 1 up, 0 down | May 6, 2026 | $204.92M |
| Dec 31, 2025 | $0.14 | $0.35 | $0.27 - $0.41 | -60.00% | Miss | -6.7% | 5 | 3 up, 0 down | Feb 26, 2026 | $192.57M |
| Sep 30, 2025 | $0.16 | $0.22 | $0.11 - $0.33 | -27.27% | Miss | +700.0% | 6 | 0 up, 1 down | Nov 3, 2025 | $161.71M |
| Jun 30, 2025 | $0.17 | $0.29 | $0.16 - $0.61 | -41.38% | Miss | +325.0% | 5 | 1 up, 0 down | Aug 4, 2025 | $141.15M |
| Mar 31, 2025 | $0.03 | $0.17 | $0.12 - $0.23 | -82.35% | Miss | N/A | 5 | 0 up, 1 down | May 5, 2025 | $120.86M |
| Dec 31, 2024 | $0.15 | $0.09 | $0.06 - $0.57 | +66.67% | Beat | N/A | 5 | 0 up, 0 down | Mar 3, 2025 | $108.19M |
| Sep 30, 2024 | $0.02 | $0.03 | -$0.05 - $0.08 | -33.33% | Miss | -97.3% | 8 | 0 up, 0 down | Nov 4, 2024 | $83.88M |
| Jun 30, 2024 | $0.04 | -$0.04 | -$0.09 - -$0.02 | +200.00% | Beat | N/A | 7 | 0 up, 0 down | Aug 6, 2024 | $73.47M |
| Mar 31, 2024 | -$0.07 | -$0.04 | -$0.12 - $0.05 | -75.00% | Miss | N/A | 7 | 0 up, 0 down | May 1, 2024 | $63.47M |
| Dec 31, 2023 | -$0.10 | -$0.10 | -$0.17 - -$0.04 | 0.00% | In line | N/A | 7 | 1 up, 0 down | Feb 28, 2024 | $43.97M |
| Sep 30, 2023 | $0.73 | $0.10 | -$0.28 - $0.62 | +630.00% | Beat | N/A | 7 | 0 up, 1 down | Nov 1, 2023 | $165.81M |
| Jun 30, 2023 | -$0.34 | -$0.25 | -$0.31 - -$0.20 | -36.00% | Miss | N/A | 8 | 1 up, 0 down | Aug 1, 2023 | $16.07M |
| Mar 31, 2023 | -$0.28 | -$0.34 | -$0.50 - -$0.31 | +17.65% | Beat | N/A | 7 | 1 up, 0 down | May 1, 2023 | $7.80M |
| Dec 31, 2022 | -$0.39 | -$0.26 | -$0.34 - -$0.13 | -50.00% | Miss | N/A | 8 | 1 up, 0 down | Feb 28, 2023 | $81000 |
| Sep 30, 2022 | -$0.26 | -$0.38 | -$0.47 - -$0.19 | +31.58% | Beat | N/A | 7 | 0 up, 0 down | Nov 10, 2022 | $94000 |
| Jun 30, 2022 | -$0.30 | -$0.57 | -$0.74 - -$0.37 | +47.37% | Beat | N/A | 7 | 0 up, 0 down | Aug 8, 2022 | $594000 |
| Mar 31, 2022 | -$0.51 | -$0.59 | -$0.80 - -$0.45 | +13.56% | Beat | N/A | 7 | 3 up, 0 down | May 10, 2022 | $2.02M |
| Dec 31, 2021 | -$0.70 | -$0.68 | -$0.77 - -$0.45 | -2.94% | Miss | N/A | 7 | N/A | Mar 1, 2022 | $2.32M |
| Sep 30, 2021 | -$0.65 | -$0.57 | -$0.61 - -$0.48 | -14.04% | Miss | N/A | 7 | N/A | Nov 4, 2021 | $2.03M |
| Jun 30, 2021 | -$0.59 | -$0.50 | -$0.56 - -$0.46 | -18.00% | Miss | N/A | 6 | N/A | Aug 2, 2021 | $1.54M |
| Mar 31, 2021 | -$0.69 | -$0.49 | -$0.65 - -$0.35 | -40.82% | Miss | N/A | 6 | N/A | May 10, 2021 | $793000 |
| Dec 31, 2020 | -$0.72 | -$0.61 | -$0.72 - -$0.43 | -18.03% | Miss | N/A | 6 | N/A | Mar 2, 2021 | $38000 |
| Sep 30, 2020 | -$0.73 | -$0.44 | -$0.48 - -$0.32 | -65.91% | Miss | N/A | 6 | N/A | Nov 9, 2020 | $38000 |
| Jun 30, 2020 | -$0.47 | -$0.33 | -$0.41 - -$0.27 | -42.42% | Miss | N/A | 5 | N/A | Aug 10, 2020 | $38000 |
| Mar 31, 2020 | -$0.48 | -$0.37 | -$0.49 - -$0.27 | -29.73% | Miss | N/A | 4 | N/A | May 11, 2020 | $38000 |
| Dec 31, 2019 | -$0.44 | -$0.46 | -$0.65 - -$0.29 | +4.35% | Beat | N/A | 5 | N/A | Mar 3, 2020 | $38000 |
| Sep 30, 2019 | -$0.69 | -$0.35 | -$0.37 - -$0.28 | -97.14% | Miss | N/A | 4 | N/A | Nov 12, 2019 | $38000 |
| Jun 30, 2019 | -$0.42 | -$0.42 | -$0.48 - -$0.30 | 0.00% | In line | N/A | 6 | N/A | Aug 9, 2019 | $38000 |
| Mar 31, 2019 | -$0.43 | -$0.44 | -$0.49 - -$0.32 | +2.27% | Beat | N/A | 6 | N/A | May 10, 2019 | $38000 |
| Dec 31, 2018 | -$0.69 | -$0.44 | -$0.49 - -$0.41 | -56.82% | Miss | N/A | 5 | N/A | Mar 1, 2019 | $38000 |
| Sep 30, 2018 | -$0.43 | -$0.50 | -$0.58 - -$0.48 | +14.00% | Beat | N/A | 6 | N/A | Nov 9, 2018 | $38000 |
| Jun 30, 2018 | -$0.59 | -$0.50 | -$0.58 - -$0.41 | -18.00% | Miss | N/A | 6 | N/A | Aug 7, 2018 | $38000 |
| Mar 31, 2018 | -$0.59 | -$0.42 | -$0.48 - -$0.34 | -40.48% | Miss | N/A | 6 | N/A | May 8, 2018 | $38000 |
| Dec 31, 2017 | -$0.46 | -$0.44 | -$0.49 - -$0.32 | -4.55% | Miss | N/A | 6 | N/A | Mar 8, 2018 | $38000 |
| Sep 30, 2017 | -$0.48 | -$0.40 | -$0.51 - -$0.29 | -20.00% | Miss | N/A | 4 | N/A | Nov 8, 2017 | $38000 |
| Jun 30, 2017 | -$0.45 | -$0.38 | -$0.52 - -$0.32 | -18.42% | Miss | N/A | 4 | N/A | Aug 9, 2017 | $38000 |
| Mar 31, 2017 | -$0.52 | -$0.36 | N/A | -44.44% | Miss | N/A | N/A | N/A | May 5, 2017 | $38000 |
| Dec 31, 2016 | -$0.48 | -$0.36 | N/A | -33.33% | Miss | N/A | N/A | N/A | Mar 10, 2017 | $37714 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.50, up 257.1% from the year before. It was -$1.59 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.50 | +257.1% |
| Dec 31, 2024 | $0.14 | +1300.0% |
| Dec 31, 2023 | $0.01 | N/A |
| Dec 31, 2022 | -$1.46 | N/A |
| Dec 31, 2021 | -$2.63 | N/A |
| Dec 31, 2020 | -$2.40 | N/A |
| Dec 31, 2019 | -$1.98 | N/A |
| Dec 31, 2018 | -$2.30 | N/A |
| Dec 31, 2017 | -$1.91 | N/A |
| Dec 31, 2016 | -$1.59 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,800 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,760 | 12 | |
| 2026Q2 | Jun 30, 2026 | 6,733 | 12 | |
| 2026Q1 | Mar 31, 2026 | 4,833 | 13 | |
| 2025Q4 | Dec 31, 2025 | 4,816 | 12 | |
| 2025Q3 | Sep 30, 2025 | 4,451 | 13 | |
| 2025Q2 | Jun 30, 2025 | 3,613 | 11 | |
| 2025Q1 | Mar 31, 2025 | 4,231 | 11 | |
| 2024Q4 | Dec 31, 2024 | 5,654 | 10 |
2026Q3 Earnings Call
Opening remarks
Jenna Bosco Chief Communications Officer Thank you. Welcome, everyone, and thank you for joining us this morning. I'm Jenna Bosco, and with me to discuss TG Therapeutics' Third Quarter 2026 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Hari Miskin, our Chief Development Officer; Adam Waldman, our Chief Commercial Officer; and Sean Power, our Chief Financial Officer. Following our safe harbor statement, Mike will begin with an overview of our recent corporate developments. Hari will then discuss highlights from our recent data presentation, followed by Adam, who will provide an update on our commercial efforts. Sean will conclude our prepared remarks with a review of our financial results before we open the call for Q&A. Before we begin, I'd like to remind everyone that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include expectations regarding our future operating and financial performance, including sales trends, revenue guidance, projected milestones, development plans, and the outlook for our marketed products and our pipeline products. Please note that these statements are subject to risks and uncertainties that can cause our actual results to differ materially from those indicated. These risks are detailed in our SEC filings. Additionally, any forward-looking statements made today reflect our views only as of this date, and we disclaim any obligation to update or revise them. As a reminder, this conference call is being recorded and will be available for replay for the next 30 days on our website at www.tgtherapeutics.com. With that, I'll now turn the call over to Mike Weiss, our CEO.
Michael Weiss Chairman and Chief Executive Officer Thank you, Jenna, and good morning, everyone. We appreciate you joining us today. I'm pleased to report another strong quarter for TG with meaningful progress across both our commercial business and development programs. Global revenue for the quarter was approximately $260 million, including $233 million in U.S. BRIUMVI net revenue. With solid third quarter performance and trends pointing to a strong fourth quarter, we're raising our full year global revenue guidance to $1 billion for 2026, a pretty remarkable accomplishment less than four years after launching BRIUMVI. I'd like to pause here to congratulate our team for their hard work and dedication to the MS community and to TG. And as they know, we're just getting started. $1 billion in annual revenue is an important milestone, but I don't believe it comes close to defining the opportunity ahead of us. On our last call, I described BRIUMVI as a starting line for TG, providing the commercial capabilities, financial resources, and scientific foundation to build a value creation engine.
Frequently Asked Questions About TGTX
When is TG Therapeutics's next earnings date?
TG Therapeutics's next earnings report is expected for Jan 11, 2027.
Did TGTX beat earnings estimates last quarter?
Yes. TG Therapeutics reported EPS of $0.35 for the quarter ended Sep 30, 2026, above the $0.28 estimate, a 25.00% surprise.
What EPS do analysts expect from TGTX next quarter?
The consensus EPS estimate for TG Therapeutics for the quarter ending Dec 31, 2026 is $0.56 from 10 analysts, with estimates from $0.32 to $0.72.
How often does TGTX beat earnings estimates?
TG Therapeutics beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -30.36%.
TGTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors